Ibogaine cardiac safety will remain the primary stated regulatory bottleneck blocking IND expansion in the US through June 30, 2027, with no FDA formal guidance issued permitting expanded ibogaine trials without mandatory cardiac monitoring protocols.

Ibogaine is a powerful plant medicine that can affect heart rhythm (a condition called QTc prolongation that can cause sudden cardiac death). The FDA (the US drug regulator) requires anyone running an ibogaine clinical trial to monitor patients' hearts carefully. Until June 30, 2027, the FDA will not issue new written guidance that lets researchers skip or reduce heart monitoring, even though heart monitoring makes trials expensive and hard to run at scale.

FDA's cardiac safety concern is structurally entrenched: QTc prolongation data from existing studies gives the agency defensible scientific grounds to require monitoring that most trial sponsors cannot easily implement at scale. This is not a solvable problem within 12 months without a dedicated safety study. The resolution criterion is conservative (absence of permissive guidance) and verifiable via the FDA IND database and public communications. Confidence trimmed from 0.79 to account for the possibility of a narrow FDA pathway for single-site academic INDs.